We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Agronomics Limited | ANIC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.06 | -1.48% | 3.99 | 16:35:19 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.05 | 4.00 | 4.05 | 3.99 | 4.05 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 28/11/2024 16:10 by quepassa no need to be so confrontational and defensive.you misunderstood my post and please read it again i expect failed investments, as i mentioned before, and in some ways there are fewer in Agronomics than one should have perhaps expected in a fund of start-ups and early-stage investments. i was addressing your over-generalised statement that all RNS announcements are material events and I illustrated that they are not. fifty RNS's in less than a year will bring about investor fatigue and diminish investor interest in them. good luck and let's hope it works out for everybody's sake. But one thing is for sure - the current share price and its mighty fall tell a sorry tale - and it seems to me that something major has to change to improve investor sentiment and investor confidence in Agronomics. Something more than this ongoing surfeit of RNS's. And this is especially so at a time when many other AIM-listed specialist funds have already started moving ahead significantly. all imo. dyor. qp |
Posted at 28/11/2024 10:55 by quepassa the small-cap and AIM market has wised up in recent times.the old tricks of levitating share prices by frequent news releases and announcements has passed its sell-by date. investors are nowadays much more discerning about the quality of news releases and more interested in concrete actions and events rather than glossy words and jam-tomorrow announcements. I did a google/youtube search to see if there were any new presentations or talks since the new interim ceo took over but the google search came back with no result. with Anthony Chow, you have to give him credit that he was very visible on the CellAg circuit and attended/presented at events non-stop. all imo. dyor. qp |
Posted at 14/11/2024 07:43 by nanopayments By "II’s" I'm assuming you mean institutional investors. Insiders and institutional investors hold 26% of shares outstanding, so shares would have to be bought on the open market to get to a majority. I highly doubt there would be enough retail interest, even at 2X current prices. Silly of you to not do more research. |
Posted at 08/11/2024 15:45 by quepassa you might be right but that's not the line which was fed to the market:-"Philip is a first class executive, with years of experience identifying and realising value from great companies and technologies. I have worked with him for a number of years at New Agrarian Company and I have great confidence that he will provide the necessary skills to bring success to Shellbay, and in particular the Agronomics portfolio. The share price remains extremely disappointing notwithstanding general poor market conditions and sentiment, and the discount to the Company's net asset value is unacceptable. I would like to thank Anthony Chow for his work building the portfolio, but between Philip and I, supported by the rest of the Board, we will ensure investors understand the great value opportunity that exists currently, the enormous strides that have been made by companies in the portfolio recently, and the great potential of these technologies." Interim or not, after 6 weeks in situ, surely investors could have expected at least a brief self-introduction or fleeting appearance . all imo. dyor qp |
Posted at 28/10/2024 08:32 by 1chrism A view on AIM that us investors are well aware ofhttps://www.thegua |
Posted at 19/10/2024 09:35 by 1chrism The downward grind continues. In the vain hope to rationalise the spiral what's the general feeling about causal relations: pricing in Rachel Reeves doomsday budget (for investors), delay and therefore uncertainty about Liberation Labs, just AIM, lack of revenue, public opinion of cellular agriculture (lab meat)? A bit of all of the above, or something else.It was pleasing to see AIM chief, Stuttard come out publicly and say that the market knows what's coming. As the whipping boy of the global markets what are the thoughts that halloween is going to be ghoulish for our ANIC?!https://www.ci |
Posted at 16/10/2024 11:56 by 1chrism So the word from investors is, "comon guys, be morw ambitious!"? |
Posted at 15/10/2024 08:36 by 1chrism I agree Nano, it is a relief to hear some news on funding but also it is by no stretch, money to turn on those big beautiful fermentation tanks. I think they need around $35m USD ( happy to be corrected).The 200% certainly supports Warner's confidence and lets hope that grows confidence in investors (and quickly). I share your worry on Trump and it very much depends on the ole echo chamber but he is increasingly baring a resemblance to Manchester United FC. First time round (class of '91) Trump came in fighting and the opposition were not prepared for that anti politician stance. Having now lost (thrown away) his old crew, doing the same thing he did in '16 ('91) just is not working: on the pitch/podium no one can say what he stands for off the pitch, he is just expensive. |
Posted at 08/10/2024 18:25 by 1chrism In terms of referring to the Chair/CEO/Founder role I think broadly I am agreeing with you here insofar as there is no one above when it comes to making the decisions.The buyback swerve was explained in a Anthony Chow interview, I think it was an investor presentation in April. However, also worth noting that the scheme was not presented as a dead cert - absolutely I would have liked it to go ahead. Your point about prior knowledge I find awkward as it relies heavily on the pattern spotting that is found in popular conspiracy theory.Im not sure what you are saying the governance has done to harm the company. The portfolio is in great shape and unless we get some bad news on Liberation Labs, more frustration, more patience.I do also agree that the total removal of Anthony Chow is odd. I think investors should get more info than a 2m share buy. |
Posted at 11/8/2024 00:00 by masurenguy Start-ups face the slaughterhouse as lab-grown meat loses its appealHealth fears and high prices have put consumers and investors off an industry once showered with funding amid hopes that it could save animals and the planet When the time came to shut down his lab-grown meat start-up for good, British entrepreneur Joshua March took his team out for a farewell lunch. After more than five years, $40 million in venture capital funding, SciFi Foods, their Hayward, California firm, closed its doors in June. Potentially, March reckons, SciFi may soon be joined by dozens of other start-ups that, only a few years ago, were being showered with billions of dollars by investors amid predictions that “cultivated meat” factories would replace slaughterhouses and lighten the load that large-scale livestock has on the planet. More than 80 companies have been funded in the past 5 years. Now, however, once high flyers are struggling. Jim Mellon is not so pessimistic. His London-listed Agronomics, an investment company specialising in “cellular agriculture”, has participated in 6 of the 7 largest financings in the sector in the past year. Accountants say Agronomics’ portfolio of stakes in private companies should give it a market value of 18p per share, but that price has plunged to 5.5p; its shares stood at 28p three years ago. “The discount is absolutely vast. I can’t explain it,” Mellon said. “I think that ultimately the cycle will turn again.” That may happen. The question is: how many companies will be left standing when it does? Complete article: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
